九洲药业(603456) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥1,321,966,893.34, representing a decrease of 6.79% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2023 was ¥345,043,114.27, an increase of 25.39% year-over-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥338,903,898.61, up 15.16% from the previous year[3]. - The company achieved a net profit of ¥966,770,643.95 for the first three quarters of 2023, a growth of 30.08% year-over-year[5]. - Total revenue for the first three quarters of 2023 reached ¥4,576,609,415.43, an increase of 4.65% compared to ¥4,372,695,484.55 in the same period of 2022[20]. - Net profit for the third quarter of 2023 was ¥964,436,582.77, a significant increase from ¥741,479,246.24 in the same quarter of 2022, representing a growth of 30.1%[22]. - Total comprehensive income for the third quarter of 2023 reached ¥970,221,909.79, an increase from ¥744,796,314.27 in the same period of 2022, reflecting a growth of approximately 30.3%[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥11,294,589,302.21, reflecting a 42.73% increase compared to the end of the previous year[4]. - The company's total liabilities increased to ¥2,822,433,926.27, up from ¥2,541,795,984.35, reflecting a growth of 11.06%[19]. - The total non-current liabilities amounted to ¥605,084,551.71, compared to ¥327,802,914.39 in the previous year, reflecting an increase of 84.6%[19]. - The equity attributable to shareholders at the end of the reporting period was ¥8,399,568,882.88, which is a 58.59% increase year-over-year[4]. - Owner's equity rose to ¥8,472,155,375.94, compared to ¥5,371,479,777.97 in the previous year, marking an increase of 57.1%[19]. - The company's total assets reached ¥11,294,589,302.21, up from ¥7,913,275,762.32, indicating a growth of 42.5%[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 30,210[10]. - Zhejiang Zhongbei Jiuzhou Group Co., Ltd. holds 283,518,812 shares, accounting for 31.52% of the total shares[10]. - The top ten shareholders include various institutional and individual investors, with the largest being Zhejiang Zhongbei Jiuzhou Group Co., Ltd.[12]. Cash Flow and Investments - The company's cash and cash equivalents as of September 30, 2023, amount to ¥3,918,776,401.11, a significant increase from ¥1,095,425,577.49 at the end of 2022[15]. - Cash flow from operating activities for the first three quarters of 2023 was ¥4,567,723,344.06, slightly down from ¥4,669,492,400.65 in the same period of 2022, a decrease of about 2.2%[24]. - Net cash flow from operating activities for Q3 2023 was ¥1,145,267,855.24, compared to ¥1,236,399,937.86 in Q3 2022, indicating a decline of approximately 7.4%[25]. - Cash inflow from financing activities in the first three quarters of 2023 was ¥4,153,559,971.42, compared to ¥928,970,704.90 in the same period of 2022, showing a substantial increase of approximately 347.5%[25]. - The company reported a net cash flow from financing activities of ¥2,711,869,531.65 in Q3 2023, a significant improvement from a net outflow of ¥473,830,009.23 in Q3 2022[26]. - The company’s cash outflow for investing activities in the first three quarters of 2023 was ¥752,391,080.56, compared to ¥530,070,596.20 in the same period of 2022, indicating an increase of about 41.8%[25]. Operational Efficiency - Total operating costs decreased to ¥3,422,488,804.64, down 0.51% from ¥3,439,860,576.73 year-over-year[20]. - Research and development expenses for the first three quarters of 2023 were ¥239,837,436.31, up from ¥227,413,281.50 in the same period last year, indicating an increase of 5.8%[21]. - The company is focusing on expanding its CDMO business and enhancing its project-oriented management model to improve customer pipelines and product delivery capabilities[5]. - The company is committed to maintaining high-quality development and deepening partnerships with clients in the pharmaceutical industry[4]. Other Financial Metrics - The basic earnings per share for Q3 2023 was ¥0.41, an increase of 24.24% compared to the same period last year[3]. - Basic earnings per share for Q3 2023 were ¥1.09, up from ¥0.90 in Q3 2022, representing a growth of 21.1%[23]. - The company reported a financial income of ¥64,205,991.87, a substantial increase from ¥8,310,888.95 in the previous year[21]. - Non-recurring gains for the reporting period included government subsidies amounting to ¥9,817,764.47[6]. - The company has a long-term equity investment of ¥58,340,424.38, down from ¥63,460,834.04 year-over-year[17]. - The company has a goodwill of ¥110,347,517.89, slightly down from ¥111,111,178.78 year-over-year[17]. - Accounts receivable increased to ¥1,101,670,154.63 from ¥671,108,321.42 year-over-year[15]. - Inventory decreased to ¥1,818,293,900.36 from ¥2,021,495,421.23 year-over-year[17]. - The company reported a total current asset of ¥7,020,475,112.00, compared to ¥3,993,279,203.06 at the end of 2022[17]. - The capital reserve increased significantly to ¥4,494,583,690.14 from ¥2,058,450,232.11, representing a growth of 118.4%[19].